Intervention Review

Depot perphenazine decanoate and enanthate for schizophrenia

  1. Anthony David1,*,
  2. Seema N Quraishi1,
  3. John Rathbone2

Editorial Group: Cochrane Schizophrenia Group

Published Online: 20 JUL 2005

Assessed as up-to-date: 24 MAY 2005

DOI: 10.1002/14651858.CD001717.pub2


How to Cite

David A, Quraishi SN, Rathbone J. Depot perphenazine decanoate and enanthate for schizophrenia. Cochrane Database of Systematic Reviews 2005, Issue 3. Art. No.: CD001717. DOI: 10.1002/14651858.CD001717.pub2.

Author Information

  1. 1

    Institute of Psychiatry, London, UK

  2. 2

    Institute of Mental Health, Cochrane Schizophrenia Group, Nottingham, UK

*Anthony David, Institute of Psychiatry, De Crespigny Park, BOX PO68, London, SE5 8AF, UK. a.david@iop.kcl.ac.uk.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 20 JUL 2005

SEARCH

Cited in:

CrossRef

This article has been cited by:

  1. 1
    P.-M. Llorca, Indications des NAP : précoces ou tardives ?, L'Encéphale, 2008, 34, S232

    CrossRef

  2. 2
    Marianna Purgato, Clive E Adams, Bromperidol decanoate (depot) for schizophrenia, The Cochrane Library,
  3. 3
    Marianna Purgato, Clive E Adams, Bromperidol decanoate (depot) for schizophrenia, The Cochrane Library,